Literature DB >> 32099037

A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia.

Prithviraj Bose1, Srdan Verstovsek1, Jorge E Cortes1, Susan Tse1, Yvonne Gasior1, Nitin Jain1, Elias J Jabbour1, Zeev Estrov1, Yesid Alvarado1, Courtney D DiNardo1, Naveen Pemmaraju1, Steven M Kornblau1, Tapan M Kadia1, Naval G Daver1, Kiran Naqvi1, Nicholas J Short1, Lucia Masarova1, John Villareal1, Sherry A Pierce1, Graciela Nogueras-Gonzalez2, Xuelin Huang2, Guillermo Garcia-Manero1, Hagop M Kantarjian1, Farhad Ravandi3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32099037     DOI： 10.1038/s41375-020-0778-0

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  1 in total

Review 1.  Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors.

Authors:  S Cerquozzi; A Tefferi
Journal:  Blood Cancer J       Date:  2015-11-13       Impact factor: 11.037
  1 in total
  9 in total

Review 1.  Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs.

Authors:  Lucia Masarova; Courtney D DiNardo; Prithviraj Bose; Naveen Pemmaraju; Naval G Daver; Tapan M Kadia; Helen T Chifotides; Lingsha Zhou; Gautam Borthakur; Zeev Estrov; Marina Konopleva; Srdan Verstovsek
Journal:  Blood Adv       Date:  2021-04-27

Review 2.  Genomics of MPN progression.

Authors:  Anand A Patel; Olatoyosi Odenike
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

Review 3.  Novel Therapies in Myeloproliferative Neoplasms: Beyond JAK Inhibitor Monotherapy.

Authors:  Sophia S Lee; Srdan Verstovsek; Naveen Pemmaraju
Journal:  J Immunother Precis Oncol       Date:  2021-06-29

Review 4.  Bone Marrow Aging and the Leukaemia-Induced Senescence of Mesenchymal Stem/Stromal Cells: Exploring Similarities.

Authors:  Paola Fernanda Ruiz-Aparicio; Jean-Paul Vernot
Journal:  J Pers Med       Date:  2022-04-29

5.  Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase.

Authors:  John O Mascarenhas; Raajit K Rampal; Heidi E Kosiorek; Rupali Bhave; Elizabeth Hexner; Eunice S Wang; Aaron Gerds; Camille N Abboud; Marina Kremyanskaya; Dimitry Berenzon; Olatoyosi Odenike; Noushin Farnoud; Aishwarya Krishnan; Rona Singer Weinberg; Erin McGovern; Mohamed E Salama; Vesna Najfeld; Juan S Medina-Martinez; Juan E Arango Ossa; Max F Levine; Yangyu Zhou; Lonette Sandy; Mark L Heaney; Ross L Levine; Ruben A Mesa; Amylou C Dueck; Ronald Hoffman
Journal:  Blood Adv       Date:  2020-10-27

Review 6.  Accelerated Phase of Myeloproliferative Neoplasms.

Authors:  Omar A Shahin; Helen T Chifotides; Prithviraj Bose; Lucia Masarova; Srdan Verstovsek
Journal:  Acta Haematol       Date:  2021-04-21       Impact factor: 2.195

Review 7.  Immunotherapy in Myeloproliferative Diseases.

Authors:  Lukas M Braun; Robert Zeiser
Journal:  Cells       Date:  2020-06-26       Impact factor: 6.600

Review 8.  Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis.

Authors:  Andrew T Kuykendall; Nathan P Horvat; Garima Pandey; Rami Komrokji; Gary W Reuther
Journal:  Cancers (Basel)       Date:  2020-08-14       Impact factor: 6.639

9.  Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors.

Authors:  Helen T Chifotides; Lucia Masarova; Mansour Alfayez; Naval Daver; Yesid Alvarado; Elias Jabbour; Marina Konopleva; Hagop M Kantarjian; Keyur P Patel; Courtney D DiNardo; Srdan Verstovsek
Journal:  Blood Adv       Date:  2020-11-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.